Vir Biotechnology (VIR) Retained Earnings (2018 - 2026)
Vir Biotechnology (VIR) posted Retained Earnings of -$1.3 billion for Q1 2026, down 10.49% sequentially from -$1.2 billion in Q4 2025, and down 50.27% YoY from -$2.7 billion in Q1 2025.
Vir Biotechnology (VIR) Retained Earnings (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Retained Earnings for 9 years, with the latest figure at -$1.3 billion in Q1 2026.
- Quarterly Retained Earnings fell 50.27% year-over-year to -$1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 50.27% YoY) and the FY2025 annual result came in at -$1.2 billion, down 69659.52% from the prior year.
- Retained Earnings retreated to -$1.3 billion in Q1 2026 per VIR's latest filing, from -$1.2 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.9 billion in Q1 2024 and troughed at -$1.3 billion in Q1 2026.
- A 5-year average of $110.0 million and a median of -$3.2 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 57659.46% in 2024, then plunged 69659.52% in 2025.
- Over 5 years, Retained Earnings stood at $1.7 billion in 2022, then climbed by 6.96% to $1.8 billion in 2023, then sank by 100.09% to -$1.7 million in 2024, then slumped by 69659.52% to -$1.2 billion in 2025, then fell by 10.49% to -$1.3 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.3 billion, -$1.2 billion, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 2.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Bn |
| Mar 31, 2026 | -1.32 Bn |
| Dec 31, 2025 | -1.20 Bn |
| Sep 30, 2025 | -1.91 Mn |
| Jun 30, 2025 | -991.71 Mn |
| Mar 31, 2025 | -880.75 Mn |
| Dec 31, 2024 | -1.72 Mn |
| Sep 30, 2024 | -655.20 Mn |
| Jun 30, 2024 | -441.48 Mn |
| Mar 31, 2024 | 1.85 Bn |
| Dec 31, 2023 | 1.83 Bn |
| Sep 30, 2023 | -121.85 Mn |
| Jun 30, 2023 | 41.56 Mn |
| Mar 31, 2023 | -3.22 Mn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | 1.68 Bn |
| Jun 30, 2022 | -7.55 Mn |
| Mar 31, 2022 | 380.00 Mn |
| Dec 31, 2021 | 1.57 Bn |
| Sep 30, 2021 | -663.90 Mn |